Abstract:Summary For randomized clinical trials where a single, primary, binary endpoint would require unfeasibly large sample sizes, composite endpoints (CEs) are widely chosen as the primary endpoint. Despite being commonly used, CEs entail challenges in designing and interpreting results. Given that the components may be of different relevance and have different effect sizes, the choice of components must be made carefully. Especially, sample size calculations for composite binary endpoints depend not only on the anticipated effect sizes and event probabilities of the composite components but also on the correlation between them. However, information on the correlation between endpoints is usually not reported in the literature which can be an obstacle for designing future sound trials. We consider two-arm randomized controlled trials with a primary composite binary endpoint and an endpoint that consists only of the clinically more important component of the CE. We propose a trial design that allows an adaptive modification of the primary endpoint based on blinded information obtained at an interim analysis. Especially, we consider a decision rule to select between a CE and its most relevant component as primary endpoint. The decision rule chooses the endpoint with the lower estimated required sample size. Additionally, the sample size is reassessed using the estimated event probabilities and correlation, and the expected effect sizes of the composite components. We investigate the statistical power and significance level under the proposed design through simulations. We show that the adaptive design is equally or more powerful than designs without adaptive modification on the primary endpoint. Besides, the targeted power is achieved even if the correlation is misspecified at the planning stage while maintaining the type 1 error. All the computations are implemented in R and illustrated by means of a peritoneal dialysis trial.

Sample Size Determination and Re‐estimation for Matched Pair Designs with Multiple Binary Endpoints

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

Power and Sample Size for Dose-Finding Studies with Survival Endpoints under Model Uncertainty.

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment

Some statistical methods for multiple endpoints in clinical trials

Antioxidant activity of oligosaccharide ester extracted from Polygala tenuifolia roots in senescence-accelerated mice

A robust likelihood approach to inference for paired multiple binary endpoints data

Sample Size Re-Estimation Without Un-Blinding for Time-to-event Outcomes in Oncology Clinical Trials

Tests for equivalence based on odds ratio for matched-pair design

Optimal sample size allocation for two‐arm superiority and non‐inferiority trials with binary endpoints

The Sample Size Re-estimation of Combining CP Method and EM Algorithm

Robust statistical inference for the matched net benefit and the matched win ratio using prioritized composite endpoints

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin

Unconditional Exact Tests for Equivalence or Noninferiority for Paired Binary Endpoints

Bridging the Gap Between Design and Analysis: Randomization Inference and Sensitivity Analysis for Matched Observational Studies with Treatment Doses

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio

Optimal exact tests for multiple binary endpoints